TY - JOUR
T1 - Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease
AU - Jain COS Consortium
AU - Moore, Ursula
AU - Gordish, Heather
AU - Diaz-Manera, Jordi
AU - James, Meredith K.
AU - Mayhew, Anna G.
AU - Guglieri, Michela
AU - Fernandez-Torron, Roberto
AU - Rufibach, Laura E.
AU - Feng, Jia
AU - Blamire, Andrew M.
AU - Carlier, Pierre G.
AU - Spuler, Simone
AU - Day, John W.
AU - Jones, Kristi J.
AU - Bharucha-Goebel, Diana X.
AU - Salort-Campana, Emmanuelle
AU - Pestronk, Alan
AU - Walter, Maggie C.
AU - Paradas, Carmen
AU - Stojkovic, Tanya
AU - Mori-Yoshimura, Madoka
AU - Bravver, Elena
AU - Pegoraro, Elena
AU - Lowes, Linda Pax
AU - Mendell, Jerry R.
AU - Bushby, Kate
AU - Straub, Volker
N1 - Funding Information:
The estimated $4 million USD needed to fund this study was provided by the Jain Foundation.
Funding Information:
Alan Pestronk reports the grant from the Jain Foundation
Funding Information:
This study has only been possible thanks to the international collaboration of several specialised centres promoted by the Jain Foundation. The Jain COS consortium would like to thank the study participants and their families for their invaluable contribution and would also like to acknowledge the ongoing support the Jain Foundation provides in the development, management, and analysis of this Study. The Jain Foundation, based in Seattle, USA, is entirely focused on LGMD2B/dysferlinopathy/Miyoshi Myopathy. The foundation does not solicit funding from patients, but instead funds research and clinical studies worldwide with the goal of finding treatments for dysferlinopathy. Please visit www.jain-foundation.org for more information about the foundation and if you are a patient suffering from dysferlinopathy, please consider enrolling into their interactive dysferlinopathy registry that seeks to build a strong, engaged, and supportive community (patients@jain-foundation.org).
Funding Information:
Andrew M. Blamire reports the grant from the Jain Foundation
Funding Information:
This study has only been possible thanks to the international collaboration of several specialised centres promoted by the Jain Foundation. The Jain COS consortium would like to thank the study participants and their families for their invaluable contribution and would also like to acknowledge the ongoing support the Jain Foundation provides in the development, management, and analysis of this Study. The Jain Foundation, based in Seattle, USA, is entirely focused on LGMD2B/dysferlinopathy/Miyoshi Myopathy. The foundation does not solicit funding from patients, but instead funds research and clinical studies worldwide with the goal of finding treatments for dysferlinopathy. Please visit www.jain-foundation.org for more information about the foundation and if you are a patient suffering from dysferlinopathy, please consider enrolling into their interactive dysferlinopathy registry that seeks to build a strong, engaged, and supportive community (patients@jain-foundation.org). Statistics conducted by Dr Ursula Moore, academic affiliation 1. Statistical approach advised by Dr Heather Gordish Dressman, academic affiliation 2 and 3. The estimated $4 million USD needed to fund this study was provided by the Jain Foundation. Volker Straub was supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1, The estimated $4 million USD needed to fund this study was provided by the Jain Foundation. Volker Straub was supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1, As detailed below individuals disclosure interests outside the scope of this work and the grant from the Jain Foundation. As a natural history study, there are no products that are being tested in this study. Therefore in the view of the corresponding author and consortium lead there are no conflicts of interest relevant to this work. Ursula Moore reports the grant from the Jain Foundation, Heather Gordish reports the grant from the Jain Foundation, Jordi Díaz-Manera reports no disclosures, Meredith K. James reports the grant from the Jain Foundation, Anna G. Mayhew reports no disclosures, Michela Guglieri reports the grant from the Jain Foundation, Roberto Ferenandez Torron reports no disclosures, Laura E. Rufibach works for the Jain Foundation, Jia Feng reports no disclosures, Andrew M. Blamire reports the grant from the Jain Foundation, Pierre G. Carlier MD reports no disclosures, Simone Spuler reports no disclosures, John W. Day reports the grant from the Jain Foundation, personal fees from Biogen, Ionis, Avexis, Roche, Sarepta, Sanofi, Genzyme, Scholar Rock, Pfizer plus patents from Athena Diagnostics. Kristi J. Jones reports no disclosures, Diana X. Bharucha-Goebel reports membership of the Gene Therapy Network (Avexis), Emmanuelle Salort-Campana reports no disclosures, Alan Pestronk reports the grant from the Jain Foundation, Sabine Krause reports no disclosures, Olivia Schreiber-Katz reports grants from the German Neuromuscular Society (DGM e.V.) and from the Young Faculty Program of Hannover Medical School; personal fees and non-financial support from Biogen GmbH, outside the submitted work. Maggie C. Walter reports advisory board membership for Avexis, Biogen, Novartis, Roche, Santhera, Sarepta, PTC Therapeutics, Ultragenyx, Wave Sciences, plus personal fees from Novartis, Biogen, Ultragenyx, Santhera, PTC Therapeutics, Ask Bio, Audentes Therapeutics, Fulcrum Therapeutics, GIG Consul, Guidepoint Global, Novartis, PTC, Gruenthal Pharma, Carmen Paradas reports no disclosures, Tanya Stojkovic reports no disclosures, Madoka Mori-Yoshimura reports no disclosures, Elena Bravver deceased, Elena Pegoraro reports grants, personal fees and non financial support from Santhera, personal fees and nonfinancial support from Sarepta, Personal fees and non financial support from PTC pharmaceuticals all outside this submitted work. Linda Pax Lowes reports no disclosures, Jerry R. Mendell reports no disclosures, Kate Bushby reports no disclosures, Volker Straub reports the Jain Foundation grant and other grants and personal fees from Sarepta Therapeutics.
Publisher Copyright:
© 2021 The Authors
PY - 2021/4
Y1 - 2021/4
N2 - This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data to perform a cross-sectional review of the pattern of muscle involvement in 168 patients from the Jain Foundation's international Clinical Outcomes Study for Dysferlinopathy. We demonstrated that there is no clinically relevant difference in proximal vs distal involvement between diagnosis. There is a continuum of distal involvement at any given degree of proximal involvement and patients do not fall into discrete distally or proximally affected groups. There appeared to be geographical preference for a particular diagnosis, with MMD1 being more common in Japan and LGMDR2 in Europe and the USA. We conclude that the dysferlinopathies do not form two distinct phenotypic groups and therefore should not be split into separate cohorts of LGMDR2 and MM for the purposes of clinical management, enrolment in clinical trials or access to subsequent treatments.
AB - This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data to perform a cross-sectional review of the pattern of muscle involvement in 168 patients from the Jain Foundation's international Clinical Outcomes Study for Dysferlinopathy. We demonstrated that there is no clinically relevant difference in proximal vs distal involvement between diagnosis. There is a continuum of distal involvement at any given degree of proximal involvement and patients do not fall into discrete distally or proximally affected groups. There appeared to be geographical preference for a particular diagnosis, with MMD1 being more common in Japan and LGMDR2 in Europe and the USA. We conclude that the dysferlinopathies do not form two distinct phenotypic groups and therefore should not be split into separate cohorts of LGMDR2 and MM for the purposes of clinical management, enrolment in clinical trials or access to subsequent treatments.
KW - [16] Clinical neurology examination
KW - [176] All neuromuscular disease
KW - [185] Muscle disease
KW - [21] Clinical trials methodology
KW - [54] Cohort study
UR - http://www.scopus.com/inward/record.url?scp=85101092677&partnerID=8YFLogxK
U2 - 10.1016/j.nmd.2021.01.009
DO - 10.1016/j.nmd.2021.01.009
M3 - Article
C2 - 33610434
AN - SCOPUS:85101092677
VL - 31
SP - 265
EP - 280
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
SN - 0960-8966
IS - 4
ER -